Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

In November 2023, the Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for long-term weight management. Tirzepatide has been approved for treating type 2 diabetes under the trade ...

During my State of the County address in May, I had the pleasure of introducing Kenosha County’s first new logo in more than 40 years. Developed in collaboration with members of the County Board ...

Tirzepatide is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Obstructive Sleep Apnea. According to GlobalData, Pre-Registration drugs for Obstructive Sleep Apnea ...